The US FDA may limit Covid-19 boosters to high-risk groups only, citing lack of efficacy in healthy individuals. Meanwhile, ...

The U.S. has detected the NB.1.8.1 COVID-19 variant, dominant in China, through airport screenings and health departments ...

The travelers with cases linked to the NB.1.8.1 variant have been arriving at airports in California, Washington state, ...

A panel of advisers to the U.S. Food and Drug Administration (FDA) has recommended that for the upcoming fall and winter immunization campaigns, COVID-19 vaccine makers should formulate their shots to ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are ...

The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under 65. Pfizer is reviewing the plan, while officials call for more evidence ...

The highest dividend-paying stocks in the S&P 500 right now are blue-chip stocks that yield anywhere between 6.2% and 9.3% annually. And while markets are largely flat since Jan. 1 — with a ...

A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...